Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
EcoR1 Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
EcoR1 Capital

EcoR1 Capital

Operating

EcoR1 Capital: A biotech investment advisory firm, funding R&D at all stages since 2013.

Location
San Francisco, CA, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Investments

Accent Therapeutics
Accent Therapeutics

Total Raised

$178M

Rounds

3

Series C$75MJanuary 2024
Arvinas
Arvinas
Public

Total Raised

$461.6M

Rounds

5

Post Ipo Equity$350MNovember 2023
Terremoto Biosciences
Terremoto Biosciences

Total Raised

$250M

Rounds

2

Series B$175MNovember 2023
Aligos Therapeutics
Aligos Therapeutics
Public

Total Raised

$400.6M

Rounds

5

Post Ipo Equity$92MOctober 2023
ReCode Therapeutics
ReCode Therapeutics

Total Raised

$521.8M

Rounds

6

Series B$50MSeptember 2023
Series B$259.8MOctober 2021
Actio Biosciences
Actio Biosciences

Total Raised

$55M

Rounds

1

Series A$55MSeptember 2023
Immunome
Immunome
Public

Total Raised

$218.9M

Rounds

20

Post Ipo Equity$125MJune 2023
ElevateBio
ElevateBio

Total Raised

$1.2B

Rounds

5

Series D$401MMay 2023
Paratus Sciences
Paratus Sciences

Total Raised

$100M

Rounds

1

Series A$100MFebruary 2023
Abeona Therapeutics
Abeona Therapeutics
Public

Total Raised

$354.7M

Rounds

13

Post Ipo Equity$35MNovember 2022
SpringWorks Therapeutics
SpringWorks Therapeutics
Public

Total Raised

$1B

Rounds

6

Post Ipo Equity$225MSeptember 2022
Aktis Oncology
Aktis Oncology

Total Raised

$156M

Rounds

2

Series A$84MAugust 2022
Kymera Therapeutics
Kymera Therapeutics
Public

Total Raised

$879M

Rounds

8

Post Ipo Equity$150MAugust 2022
Tempest Therapeutics
Tempest Therapeutics
Acquired

Total Raised

$90M

Rounds

4

Post Ipo Equity$15MApril 2022
2seventy bio
2seventy bio
Public

Total Raised

$315M

Rounds

4

Post Ipo Equity$170MMarch 2022
Dewpoint Therapeutics
Dewpoint Therapeutics

Total Raised

$287M

Rounds

3

Series C$150MFebruary 2022
Epikast
Epikast

Total Raised

$10M

Rounds

1

Series A$10MFebruary 2022
Eikon Therapeutics
Eikon Therapeutics

Total Raised

$772M

Rounds

4

Series B$518MJanuary 2022
Tango Therapeutics
Tango Therapeutics
Public

Total Raised

$351M

Rounds

5

Post Ipo Equity$186MAugust 2021
Cyclerion Therapeutics
Cyclerion Therapeutics
Public

Total Raised

$222M

Rounds

5

Post Ipo Equity$18MJune 2021
Ajax Therapeutics
Ajax Therapeutics

Total Raised

$40M

Rounds

1

Series Unknown$40MJune 2021
NiKang Therapeutics
NiKang Therapeutics

Total Raised

$260M

Rounds

3

Series C$200MMay 2021
Affinia Therapeutics
Affinia Therapeutics

Total Raised

$170M

Rounds

2

Series B$110MMay 2021
Janux Therapeutics
Janux Therapeutics
Public

Total Raised

$252.4M

Rounds

5

Series B$125MApril 2021